Verastem is a biopharmaceutical company developing cancer treatments in the US. Its products include Avutometinib, an orally available RAF/MEK clamp, and Defactinib, an oral FAK inhibitor. The company has several clinical trials ongoing, including RAMP 301, RAMP 201, FRAME, RAMP 204, and RAMP 205. It has license agreements with Chugai Pharmaceutical Co. and Pfizer Inc. Verastem also has a collaboration agreement with Amgen to evaluate Avutometinibs combination with Amgens KRAS-G12C inhibitor LUMAKRAS. Additionally, the company has a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem was incorporated in 2010 and is headquartered in Needham, Massachusetts.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 0.4 |